Sharps Technology Business Summary

Sharps Technology Inc. (STSS) operates as a medical device sales and distribution platform that has recently pivoted to a hybrid business model combining healthcare product commercialization with a Solana-based digital asset treasury strategy. The company generates revenue through two primary segments: the sale of its patented "smart-safety" syringe products, which feature ultra-low waste and integrated safety mechanisms, and its digital asset initiatives, which produce income via SOL staking rewards and fair-value gains from its multi-million SOL treasury. Having recently exited legacy manufacturing to streamline operations, Sharps now focuses on high-margin distribution and institutional-grade crypto-yield optimization. In the competitive landscape, Sharps contends with industry giants such as Becton Dickinson (BD), Terumo Medical, and Equashield, positioning itself as a niche, tech-forward alternative that leverages decentralized finance to bolster its balance sheet and fund medical innovation. The company is led by Principal Executive Officer and Board Member Paul K. Danner, a seasoned executive with a background as a Naval Aviator and leadership experience at multiple Nasdaq-listed firms, including Authvia and Alliance MMA. Supporting the strategic pivot is Chief Investment Officer Alice Zhang, who oversees the firm’s digital asset treasury, and CFO Andrew R. Crescenzo, who manages the company’s capital markets and financial reporting. The leadership team also includes Braden Miller as Director of Product & Manufacturing and Frank Parrado as VP of Finance. Sharps has attracted a sophisticated roster of institutional investors and strategic partners, including Saba Capital Management, Pantera Capital, and Electric Capital, alongside board members like Annemarie Tierney, a former SEC regulator. This leadership blend of traditional medical device expertise and institutional crypto-asset management reflects the company's unique dual-track growth strategy.